Dry age-related macular degeneration (AMD) significantly affects patients' daily activities and quality of life, regardless of visual impairment.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Given the substantial variability in clinical AI algorithms, implementing effective monitoring solutions is highly recommended.

Machine learning models can feasibly diagnose mild cognitive impairment in older adults by assessing their motor function.

The US Department of Veterans Affairs will no longer offer hormone replacement therapy for transgender veterans seeking treatment.

Easily available nitrous oxide canisters like "Whip-it!" can cause both temporary and lasting neurological damage or death.

Doctors in New York used a stem cell therapy to cure sickle cell anemia for the first time by modifying red blood cell production.

Presbyopia-correcting contact lenses still evade a significant number of patients with presbyopia, even as prescription rates have increased.

Young adults with myopia who attend school may benefit from lower concentration atropine, which minimizes visual performance disruptions.

The FDA has accepted for review the New Drug Application for SYD-101 (atropine sulfate) to slow the progression of myopia in children.

The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).